文章摘要
唐敏,陶莉,方倩倩,等.吲哚美辛联合生长抑素或奥曲肽预防内镜下逆行胰胆管造影术后胰腺炎的回顾性研究[J].安徽医药,2017,21(6):1091-1093.
吲哚美辛联合生长抑素或奥曲肽预防内镜下逆行胰胆管造影术后胰腺炎的回顾性研究
Retrospective analysis of different drug groups in prevention of post-ERCP pancretitis
投稿时间:2016-06-26  
DOI:
中文关键词: 内镜下逆行胰胆管造影术  内镜下逆行胰胆管造影术后胰腺炎  药物预防
英文关键词: Endoscopic retrograde cholangio-pancreatography  Post-ERCP pancreatitis  Pharmacologic prophylaxis
基金项目:
作者单位
唐敏 安徽医科大学第二附属医院消化内科,安徽 合肥 230601 
陶莉 安徽医科大学第二附属医院消化内科,安徽 合肥 230601 
方倩倩 安徽医科大学第二附属医院消化内科,安徽 合肥 230601 
李玥 安徽医科大学第二附属医院消化内科,安徽 合肥 230601 
张道权 安徽医科大学第二附属医院消化内科,安徽 合肥 230601 
周玉保 安徽医科大学第二附属医院消化内科,安徽 合肥 230601 
章礼久 安徽医科大学第二附属医院消化内科,安徽 合肥 230601 
摘要点击次数: 2280
全文下载次数: 783
中文摘要:
      目的 探讨吲哚美辛栓和生长抑素对内镜下逆行胰胆管造影(ERCP)术后胰腺炎的预防作用。方法 回顾性分析近6年的ERCP病例,调查其ERCP术后胰腺炎(PEP)发病率及术前使用吲哚美辛栓和术后用生长抑素或奥曲肽的情况。所有病人分为包含吲哚美辛组(共三个亚组分别为单药吲哚美辛组、吲哚美辛+高剂量奥曲肽组,吲哚美辛+生长抑素组);无吲哚美辛组。结果 699例病人纳入研究。PEP发病率为9.7%(68/699),重症胰腺炎发病率为0.85%(6/699)。包含吲哚美辛组比无吲哚美辛组ERCP术后胰腺炎发病率明显降低(7.6% vs 13.8%,χ2=6.882,P<0.01)。三个使用吲哚美辛亚组间比较虽差异无统计学意义(P=0.064),但是吲哚美辛+生长抑素组获得了最低的PEP发病率为3.6%(吲哚美辛+高剂量奥曲肽组为8.8%,单用吲哚美辛为11.1%)。结论 该研究提示吲哚美辛联合生长抑素可预防ERCP术后胰腺炎,但需要更严格设计的大样本随机对照研究来分析。
英文摘要:
      Objective To investigate the synergistic effect of indomethacin combined with somatostatin in post-ERCP pancreatitis.Methods ERCP patients for nearly six years in our hospital were retrospectively analyzed to investigate its incidence of post-ERCP pancretitis (PEP) and to observe the effect of indomethacin and somatostatin.All the patients were divided into indomethacin groups(including indomethacin group,indomethacin+high-Octreotide group,indomethacin+somatostatin group) and non- indomethacin groups.Results 699 patients were included in the present study,among which the incidence of PEP was 9.7% (68/699) and severe pancreatitis was 0.85%(6/699).The incidence of PEP in indomethacin groups was significantly decreased compared with in non- indomethacin groups (7.6% vs 13.8%,χ2=6.882,P<0.01).Although there was no obvious statistically significance among three sub-groups of indomethacin(P=0.064),indomethacin+somatostatin group obtained the lowest incidence of PEP (3.6 %).Conclusion Our study indicates that there is no obvious synergistic effect of indomethacin combined with somatostatin in PEP.And the large sample and randomized controlled study to investigate this problem are needed.
查看全文   查看/发表评论  下载PDF阅读器
关闭

分享按钮